Gundermann K J, Lie T S
Artif Organs. 1980 Feb;4(1):27-9. doi: 10.1111/j.1525-1594.1980.tb03896.x.
Twelve patients with acute liver failure, two patients with cirrhotic failure of the liver, and one patient in the terminal stage of cirrhotic liver were treated. The patients had grade IV or V hepatic coma. Twenty-seven perfusions were carried out, each lasting 8 to 27 hours, with one to four perfusions per patient. Eight patients with acute liver failure were brought out of the coma. Six of them showed sufficient clinical symptoms of hepatic regeneration; five of these could be discharged. These results suggest that 50% of complete clinical recovery of consciousness from grade IV or V coma in acute hepatic failure is possible with this therapy. The three patients with liver cirrhosis treated with a total of five hemoperfusions did awaken, but died because of insufficient hepatic regeneration. The serum alphafetoprotein (AFP) levels were examined. In those patients brought out of the coma, a rapid increase of AFP up to 260--500 ng/ml was observed. These levels remained high for several weeks in the patients who survived. In the patients who died of liver insufficiency, AFP levels increased only slightly or briefly, so AFP could be a good criterion for determining the prognosis for coma patients with this treatment.
对12例急性肝衰竭患者、2例肝硬化肝衰竭患者和1例肝硬化晚期患者进行了治疗。这些患者处于IV级或V级肝昏迷状态。共进行了27次灌注,每次持续8至27小时,每位患者进行1至4次灌注。8例急性肝衰竭患者从昏迷中苏醒。其中6例表现出足够的肝脏再生临床症状;其中5例可以出院。这些结果表明,通过这种疗法,急性肝衰竭患者从IV级或V级昏迷中完全恢复意识的可能性为50%。接受总共5次血液灌注治疗的3例肝硬化患者确实苏醒,但因肝脏再生不足而死亡。检测了血清甲胎蛋白(AFP)水平。在那些从昏迷中苏醒的患者中,观察到AFP迅速升高至260 - 500 ng/ml。在存活的患者中,这些水平在数周内一直保持较高。在死于肝功能不全的患者中,AFP水平仅略有升高或短暂升高,因此AFP可能是判断接受这种治疗的昏迷患者预后的一个良好标准。